12:00 AM
 | 
Nov 04, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/1 cls
Alimera Sciences Inc. (NASDAQ:ALIM) Cowen Simos Simeonidis Upgrade Outperform (from market perform) 1% $2.05
Simeonidis said Alimera is "significantly" undervalued following the recent sell-off after FDA issued a complete response letter for an NDA for Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME) (see BioCentury, Oct. 28). While Alimera is trading at around $2 per share, Simeonidis said Iluvien is worth about $4 per share in the EU, where it is approved for chronic DME, even using conservative penetration assumptions. He noted that "positive U.S. news would be all upside."
Amarin Corp. plc (NASDAQ:AMRN) Leerink Joseph Schwartz Downgrade Market perform (from...

Read the full 771 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >